Meeting
2019 ASCO Annual Meeting
Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial.
Authors
Caicun Zhou
Shanghai Pulmonary Hospital, Tongji University, Shanghai, China
Caicun Zhou , Fumio Imamura , Ying Cheng , Isamu Okamoto , Byoung Chul Cho , Meng Chih Lin , Margarita Majem , Oliver Gautschi , Jhanelle Elaine Gray , Michael J. Boyer , Juliann Chmielecki , Ryan Hartmaier , Krishna Bulusu , J Carl Barrett , Rachel Hodge , Matilde Saggese , Astrid McKeown , Suresh S. Ramalingam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02296125
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9020)
DOI
10.1200/JCO.2019.37.15_suppl.9020
Abstract #
9020
Poster Bd #
343
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE).
First Author: Melissa Lynne Johnson
Poster
2021 ASCO Annual Meeting
Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
First Author: Satoru Miura
Poster
2017 ASCO Annual Meeting
Trastuzumab and paclitaxel in patients (pts) with EGFR mutated non-small-cell lung cancer (NSCLC) that express HER2 after progression on EGFR TKI treatment.
First Author: Joop De Langen
Poster
2015 ASCO Annual Meeting
A randomized, phase III study (FLAURA) of AZD9291, a novel EGFR-TKI, versus gefitinib or erlotinib in treatment-naïve patients with advanced non-small cell lung cancer and an EGFR-TKI-sensitizing mutation.
First Author: Suresh S. Ramalingam